PCSK9 function and physiology*1

PCSK9 function and physiology*1

Bibliographic Details
Main Authors:	Andrew S. Peterson, Loren G. Fong, Stephen G. Young
Format:	Article
Language:	English
Published:	Elsevier 2008-06-01
Series:	Journal of Lipid Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227520423600

Similar Items

Editorial: PCSK9: Importance in Physiology and Pathophysiology
by: Rainer Schulz, et al.
Published: (2021-07-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

PCSK9 inhibitors
by: Baris Gencer, et al.
Published: (2015-04-01)

Safety of PCSK9 inhibitors
by: Grzegorz Grześk, et al.
Published: (2022-12-01)

Erratum: Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
by: Moumita Ghosh, et al.
Published: (2018-11-01)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
by: Sarina Ataei, et al.
Published: (2023-01-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
by: Xiao-dan Xia, et al.
Published: (2021-10-01)

PCSK9 Targeting in the Management of Hypercholesterolaemia
by: Constantine E. Kosmas, et al.
Published: (2023-10-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

Pleiotropic Effects of PCSK-9 Inhibitors
by: Marcin Basiak, et al.
Published: (2021-03-01)

PCSK9 as an Atherothrombotic Risk Factor
by: Tadeja Sotler, et al.
Published: (2023-01-01)

Phage display for targeting PCSK9
by: Nicola Ferri
Published: (2021-03-01)

PCSK9: NEW VICTORY AND HORIZONS
by: M. O. Smolina, et al.
Published: (2018-09-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
by: Ranheim Trine, et al.
Published: (2007-03-01)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
by: My-Anh Nguyen, et al.
Published: (2014-02-01)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
by: Nabil G. Seidah
Published: (2021-01-01)

Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations
by: Jessica M. Cale, et al.
Published: (2023-11-01)

Circulating PCSK9 and Risk of Myocardial Infarction
by: Lars E. Laugsand, MD, PhD, et al.
Published: (2016-12-01)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
by: Rahayu Zulkapli, et al.
Published: (2023-03-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
by: Tiny Nair
Published: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
by: Martin Jozef Péč, et al.
Published: (2023-08-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

PCSK9 and the nervous system: a no-brainer?
by: Ali K. Jaafar, et al.
Published: (2023-09-01)

Physical activity to reduce PCSK9 levels
by: Amedeo Tirandi, et al.
Published: (2022-08-01)

A Comprehensive Review of PCSK9 Inhibitors
by: Caroline Coppinger BS, et al.
Published: (2022-05-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Lipid-modifying agents, from statins to PCSK9 inhibitors
by: Preiss, D, et al.
Published: (2020)

Functional consequences of a novel variant of PCSK1.
by: Lindsay A Pickett, et al.
Published: (2013-01-01)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
by: Fengyuan Lu, et al.
Published: (2023-09-01)

Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure
by: Khalid Al-Waili, et al.
Published: (2013-01-01)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
by: Gaojun Cai, et al.
Published: (2018-09-01)

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
by: Yascara Grisel Luna Saavedra, et al.
Published: (2013-01-01)

Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
by: Humphries, SE, et al.
Published: (2009)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
by: Rolf Schreckenberg, et al.
Published: (2022-06-01)

c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway
by: David Hornby, et al.
Published: (2012-10-01)